FZ008-145 / Guangzhou Fermion, Joincare - LARVOL DELTA

A Phase 1 Study of FZ008-145 in Healthy Subjects. (clinicaltrials.gov) - P1 | N=176 | Completed | Sponsor: Guangzhou Fermion Technology Co., LTD | Recruiting ➔ Completed

Trial completion • Pain

A Phase 1 Study of FZ008-145 in Healthy Subjects. (clinicaltrials.gov) - P1 | N=190 | Recruiting | Sponsor: Guangzhou Fermion Technology Co., LTD | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Nov 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Pain

A Phase 1 Study of FZ008-145 in Healthy Subjects. (clinicaltrials.gov) - P1 | N=168 | Recruiting | Sponsor: Guangzhou Fermion Technology Co., LTD | Not yet recruiting ➔ Recruiting | N=84 ➔ 168 | Trial completion date: Aug 2025 ➔ Dec 2025 | Trial primary completion date: Jul 2025 ➔ Nov 2025

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Pain

A Phase 1 Study of FZ008-145 Solution or FZ008-145 Tablet in Healthy Subjects. (clinicaltrials.gov) - P1 | N=84 | Not yet recruiting | Sponsor: Guangzhou Fermion Technology Co., LTD

New P1 trial

Fermion announces IND Approval of Non-Addictive Pain Relief Drug FZ008-145 by China NMPA (PRNewswire) - "Guangzhou Fermion Technology Co., Ltd...has announced today that China National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) application for its non-addictive pain relief drug FZ008-145....Alongside FZ008-145, the lead pipeline FZ002-037 has completed Phase I clinical trials and is poised to initiate Phase II concept validation POC trials, positioning it the second globally and the first in China clinical drug with the same target."

New trial • Pain